|
||
Mefoxin Dosage |
||
Intended for IV use only.
Treatment: Adults: Usual Dosage Range: 1-2 g every 6-8 hrs. Dosage should be determined by susceptibility of the causative organisms, severity of infection, and the condition of the patient.
If C. trachomatis is a suspected pathogen, appropriate anti-chlamydial coverage should be added, because Mefoxin has no activity against this organism.
B Braun Mefoxin may be used in patients with reduced renal function with the following dosage adjustments:
Adults with Renal Insufficiency: Initial Loading Dose: 1-2 g may be given. After a loading dose, the recommendations for maintenance dosage may be used as a guide.
When only the serum creatinine level is available, the following formula (based on sex, weight and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function.
Patients Undergoing Hemodialysis: Loading Dose: 1-2 g should be given after each hemodialysis and the maintenance dose should be given as indicated in Table 10.
Antibiotic therapy for group A β-hemolytic streptococcal infections should be maintained for at least 10 days to guard against the risk of rheumatic fever or glomerulonephritis. In staphylococcal and other infections involving a collection of pus, surgical drainage should be carried out where indicated.
Pediatric Patients ≥3 months: Recommended
Dosage: 80-160 mg/kg of body weight/day divided into 4-6 equal doses. The higher dosages should be used for more severe or serious infections. The total daily dosage should not exceed 12 g.
At this time, no recommendation is made for pediatric patients from birth to 3 months.
In pediatric patients with renal insufficiency, the dosage and frequency of dosage should be modified consistent with the recommendations for adults.
Prevention: Effective prophylactic use depends on the time of administration. B Braun Mefoxin usually should be given ½-1 hr before the operation, which is sufficient time to achieve effective levels in the wound during the procedure. Prophylactic administration should usually be stopped within 24 hrs since continuing administration of any antibiotic increases the possibility of adverse reactions but in the majority of surgical procedures, does not reduce the incidence of subsequent infection.
For prophylactic use in uncontaminated gastrointestinal surgery, vaginal or abdominal hysterectomy, the following doses are recommended:
Adults: 2 g administered IV just prior to surgery (approximately ½-1 hr before the initial incision) followed by 2 g every 6 hrs after the 1st dose for no more than 24 hrs.
Pediatric Patients ≥3 months: 30-40 mg/kg doses may be given at the times designated as in adults.
Cesarean Section Patients: For patients undergoing cesarean section, either a single 2 g dose administered IV as soon as the umbilical cord is clamped or a 3-dose regimen consisting of 2-g given IV as soon as the umbilical cord is clamped followed by 2 g, 4 and 8 hrs after the initial dose is recommended.
Administration: The IV route is preferable for patients with bacteremia, bacterial septicemia, or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure or malignancy, particularly if shock is present or impending.
B Braun Mefoxin may be administered through the tubing system by which the patient may be receiving other IV solutions. However, during infusion of the solution containing B Braun Mefoxin, it is advisable to temporarily discontinue administration of any other solutions at the same site.
Solutions of B Braun Mefoxin, like those of most β-lactam antibiotics, should not be added to aminoglycoside solutions (eg, gentamicin sulfate, tobramycin sulfate, amikacin sulfate) because of potential interaction.
However, B Braun Mefoxin and aminoglycosides may be administered separately to the same patient.
Before using Mefoxin, tell your doctor if you are using any of the following drugs:
an antibiotic such as amikacin (Amikin), gentamicin (Garamycin), kanamycin (Kantrex), neomycin (Mycifradin, Neo-Fradin, Neo-Tab), netilmicin (Netromycin), streptomycin, or tobramycin (Nebcin, Tobi).
This list is not complete and there may be other drugs that can interact with Mefoxin. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
Drug/Laboratory Test Interactions
As with cephalothin, high concentrations of Mefoxin (>100 micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the Jaffé reaction, and produce false increases of modest degree in the levels of creatinine reported. Serum samples from patients treated with Mefoxin should not be analyzed for creatinine if withdrawn within 2 hours of drug administration.
High concentrations of Mefoxin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported.
A false-positive reaction for glucose in the urine may occur. This has been observed with CLINITEST† reagent tablets.
† Registered trademark of Ames Company, Division of Miles Laboratories, Inc.
Users | % | ||
---|---|---|---|
4 times in a day | 1 | 100.0% |
Users | % | ||
---|---|---|---|
101-200mg | 2 | 66.7% | |
501mg-1g | 1 | 33.3% |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|